NZ592288A - Antiprolactinic veterinary composition for ruminants - Google Patents

Antiprolactinic veterinary composition for ruminants

Info

Publication number
NZ592288A
NZ592288A NZ592288A NZ59228809A NZ592288A NZ 592288 A NZ592288 A NZ 592288A NZ 592288 A NZ592288 A NZ 592288A NZ 59228809 A NZ59228809 A NZ 59228809A NZ 592288 A NZ592288 A NZ 592288A
Authority
NZ
New Zealand
Prior art keywords
antiprolactinic
ruminants
veterinary composition
ergoline
amongst
Prior art date
Application number
NZ592288A
Other languages
English (en)
Inventor
Anouck Lagarde
Stephane Floch
Thierry Bertaim
Original Assignee
Ceva Sante Animale Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40527505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ592288(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ceva Sante Animale Sa filed Critical Ceva Sante Animale Sa
Publication of NZ592288A publication Critical patent/NZ592288A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ592288A 2008-10-07 2009-10-07 Antiprolactinic veterinary composition for ruminants NZ592288A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0805544A FR2936710B1 (fr) 2008-10-07 2008-10-07 Composition veterinaire antiprolactinique destinee aux ruminants
PCT/EP2009/063004 WO2010040765A1 (fr) 2008-10-07 2009-10-07 Composition veterinaire antiprolactinique destinee aux ruminants

Publications (1)

Publication Number Publication Date
NZ592288A true NZ592288A (en) 2013-03-28

Family

ID=40527505

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592288A NZ592288A (en) 2008-10-07 2009-10-07 Antiprolactinic veterinary composition for ruminants

Country Status (24)

Country Link
US (2) US9730923B2 (enExample)
EP (1) EP2349272B1 (enExample)
JP (1) JP5955561B2 (enExample)
KR (2) KR20110110091A (enExample)
CN (1) CN102215843B (enExample)
AU (1) AU2009301134B2 (enExample)
BR (1) BRPI0914064A2 (enExample)
CA (1) CA2738875C (enExample)
DK (1) DK2349272T3 (enExample)
ES (1) ES2719844T3 (enExample)
FR (1) FR2936710B1 (enExample)
HU (2) HUE043239T2 (enExample)
IL (1) IL212125B (enExample)
MA (1) MA32763B1 (enExample)
MX (1) MX2011003743A (enExample)
NO (1) NO2019028I1 (enExample)
NZ (1) NZ592288A (enExample)
PL (1) PL2349272T3 (enExample)
PT (1) PT2349272T (enExample)
RU (1) RU2528892C2 (enExample)
SI (1) SI2349272T1 (enExample)
UA (1) UA103779C2 (enExample)
WO (1) WO2010040765A1 (enExample)
ZA (1) ZA201103273B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2971423B1 (fr) 2011-02-15 2014-01-10 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
EP2995297A1 (fr) * 2014-09-09 2016-03-16 Ceva Sante Animale Compositions parentérales et leurs utilisations
WO2018101261A1 (ja) 2016-11-29 2018-06-07 国立研究開発法人国立精神・神経医療研究センター 進行型免疫性脱髄疾患の予防、発症抑制又は治療剤
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
UY38969A (es) 2019-11-28 2021-05-31 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
AR122366A1 (es) 2020-01-27 2022-09-07 Ceva Sante Animale Composición veterinaria para rumiantes lecheros para el tratamiento de la fiebre de la leche
AR122365A1 (es) 2020-01-27 2022-09-07 Ceva Sante Animale Composición veterinaria de anti-prolactina para rumiantes utilizada mediante administración intramamaria

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839171A (en) * 1984-11-30 1989-06-13 Techmix, Inc. Composition for treating impaired lactation
US4939259A (en) * 1989-07-24 1990-07-03 Eli Lilly And Company 2-oxo-pyrido[2,3-g]quinoline derivatives
AU2635599A (en) * 1999-03-17 2000-10-04 Eugen Eigenmann Use of prolactin inhibitors for the treatment of fertility problems in animal species
GB0108485D0 (en) * 2001-04-04 2001-05-23 Pfizer Ltd Combination therapy
NZ515178A (en) * 2001-11-23 2004-09-24 Agres Ltd Modulating prolactin receptors to affect a physiological response
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
GB0314469D0 (en) 2003-06-20 2003-07-23 Phico Therapeutics Ltd Antimicrobial compositions and uses thereof
CN1762495B (zh) * 2004-09-21 2011-04-06 山东绿叶制药有限公司 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺
WO2006032202A1 (fr) * 2004-09-21 2006-03-30 Shandong Luye Pharmaceutical Co., Ltd. Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
ITTO20070479A1 (it) 2007-07-02 2009-01-03 Ceva Vetem S P A Composizione veterinaria iniettabile ad attivita' anti-prolattinica

Also Published As

Publication number Publication date
SI2349272T1 (sl) 2019-07-31
HUE043239T2 (hu) 2019-08-28
PL2349272T3 (pl) 2019-08-30
KR101892559B1 (ko) 2018-08-28
CA2738875C (fr) 2017-11-21
JP5955561B2 (ja) 2016-07-20
PT2349272T (pt) 2019-05-13
RU2011118366A (ru) 2012-11-20
DK2349272T3 (da) 2019-04-29
IL212125A0 (en) 2011-06-30
UA103779C2 (ru) 2013-11-25
CA2738875A1 (fr) 2010-04-15
MA32763B1 (fr) 2011-11-01
US9730923B2 (en) 2017-08-15
RU2528892C2 (ru) 2014-09-20
IL212125B (en) 2020-06-30
KR20170017002A (ko) 2017-02-14
NO2019028I1 (no) 2019-07-05
FR2936710A1 (fr) 2010-04-09
EP2349272B1 (fr) 2019-01-16
KR20110110091A (ko) 2011-10-06
AU2009301134A1 (en) 2010-04-15
AU2009301134B2 (en) 2013-12-05
HUS1900036I1 (hu) 2019-07-29
US20130203762A1 (en) 2013-08-08
WO2010040765A1 (fr) 2010-04-15
JP2012505178A (ja) 2012-03-01
MX2011003743A (es) 2011-07-28
US9744158B2 (en) 2017-08-29
HK1161555A1 (en) 2012-07-27
ES2719844T3 (es) 2019-07-16
CN102215843B (zh) 2014-07-30
EP2349272A1 (fr) 2011-08-03
CN102215843A (zh) 2011-10-12
BRPI0914064A2 (pt) 2015-11-03
ZA201103273B (en) 2012-07-25
US20110245261A1 (en) 2011-10-06
FR2936710B1 (fr) 2011-01-07

Similar Documents

Publication Publication Date Title
NZ592288A (en) Antiprolactinic veterinary composition for ruminants
MX2009006751A (es) Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato.
ZA202201829B (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof
MA54471A (fr) Composé agoniste de récepteur thrb, son procédé de préparation et son utilisation
EP2236511A4 (en) LIGANDS OF ALPHA ADRENOCEPTORS AND OF DOPAMINE, HISTAMIN, IMIDAZOLIN AND SEROTONIN RECEPTORS AND THEIR APPLICATION THEREOF
IL214049A0 (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof
MX2021010759A (es) Regimen de dosificacion para un agonista de los receptores de s1p.
MX2009006304A (es) Nuevos compuestos de oxadiazol.
IL310378A (en) Serotonin receptor agonists that cause hallucinations and that do not cause hallucinations and methods for their preparation and use
CY1113734T1 (el) Χημικες ενωσεις
BR112013011549A2 (pt) composição compreendendo um agonista do receptor de serotonina e uma dicetopiperazina para tratar enxaquecas
SI2057122T1 (sl) Derivati 4-(2-amino-1-hidroksietil)fenola kot agonisti beta2-adrenergičnega receptorja
EP2182807A4 (en) CANNABINOID RECEPTOR ANTAGONISTS / INVERSAGONISTS TO TREAT OVERWEIGHT
MY188764A (en) Dosing regimen for a selective s1p1 receptor agonist
GB202203803D0 (en) Heterocyclic THR-# receptor agonist compound and preparation method and use thereof
DOP2007000021A (es) Procedimientos para tratar pérdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb
WO2008027988A3 (en) Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
NZ609803A (en) A2a antagonists as cognition and motor function enhancers
FR2971423B1 (fr) Composition veterinaire antiprolactinique destinee aux ruminants
PT3429993T (pt) Antagonistas/agonistas parciais seletivos do recetor d3 de dopamina; método de preparação; e sua utilização
WO2011097336A3 (en) Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor
GB202109018D0 (en) Treatment with an agonist of a 5-hydroxytryptamine (5-ht) receptor
AU2022299464A1 (en) Naltrexone for improving the effectiveness of 5-ht receptor subtype 2a, 2b or 2c agonists
MX2011008458A (es) Metodos para preparar agonistas y antagonistas del receptor s1p.
AU2021349680A9 (en) Use of sphingosine-1-phosphate receptor agonist

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 OCT 2016 BY SGA2

Effective date: 20130920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2017 BY ANAQUA SERVICES

Effective date: 20160922

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2018 BY ANAQUA SERVICES

Effective date: 20170920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2019 BY ANAQUA SERVICES

Effective date: 20180919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2020 BY ANAQUA SERVICES

Effective date: 20190918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2021 BY ANAQUA SERVICES

Effective date: 20200917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2022 BY ANAQUA SERVICES

Effective date: 20210921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2023 BY ANAQUA SERVICES

Effective date: 20220921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2024 BY ANAQUA SERVICES

Effective date: 20230921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2025 BY ANAQUA SERVICES

Effective date: 20240920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2026 BY PAVIS PAYMENTS GMBH

Effective date: 20250925